Orion Life Science

Orion Corporation is a leading Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company's primary focus areas include oncology, neurological disorders, and respiratory diseases, with its most notable product being the prostate cancer treatment Nubeqa (darolutamide), developed in partnership with Bayer. Orion also maintains a strong presence in the respiratory market with its Easyhaler inhaler technology and has an emerging pipeline of endocrine and pain therapies. Headquartered in Espoo, Finland, the company operates globally and is listed on the Nasdaq Helsinki.